UK supplied · Research use only

LABORATORY GUIDE

Retatrutide vs tirzepatide vs semaglutide: weight loss peptides compared

Published 28 September 2026 · 7 min read · View as Markdown

AT A GLANCE

Semaglutide targets GLP-1 receptors, tirzepatide targets GIP and GLP-1 receptors, and investigational retatrutide also targets the glucagon receptor. Receptor count describes their pharmacology, not comparative clinical potency or regulatory status. Licensed medicines and unapproved research materials must not be conflated; verify the identity and applicable status of each specific product independently.

Semaglutide, tirzepatide and retatrutide are three generations of incretin-based peptides. The key difference between them is how many receptors each one activates: one, two or three.

SemaglutideTirzepatideRetatrutide
Receptor targetsGLP-1GIP and GLP-1GIP, GLP-1 and glucagon
ClassSingle agonistDual agonistTriple agonist
Length31 amino acids39 amino acids39 amino acids
BackboneGLP-1GIPGIP
Half-life extensionC18 fatty diacidC20 fatty diacidC20 fatty diacid
Approx. molecular weight4,114 Da4,813 Da4,731 Da

Semaglutide: the GLP-1 benchmark

Semaglutide is a GLP-1 analogue with substitutions that protect it from DPP-4 and a fatty diacid chain that binds albumin. With the largest body of published data of the three, it is the usual reference compound for GLP-1 receptor research.

Tirzepatide: adding GIP

Tirzepatide is built on a GIP backbone and activates both GIP and GLP-1 receptors, with greater relative activity at the GIP receptor. Comparing it with semaglutide helps separate GLP-1 receptor effects from combined incretin effects.

Retatrutide: adding glucagon

Retatrutide adds glucagon receptor agonism. Glucagon receptor activation is studied for its effects on energy expenditure and hepatic lipid metabolism, which makes retatrutide a tool for studying what a third receptor adds beyond dual incretin agonism. Its phase 2 results were published in 2023 and phase 3 programmes are ongoing.

Choosing a compound for your study

Studies that isolate GLP-1 receptor effects typically use semaglutide. Studies of combined incretin signalling use tirzepatide, often with semaglutide as a comparator. Studies of glucagon receptor contribution use retatrutide alongside one or both of the others.

This guide covers general peptide chemistry. Vyrax Labs products are sold as research compounds, and nothing here is medical advice.

Compounds in this guide

More guides